Xphyto upgrades to OTCQB, moves closer to commercialization with saliva-based coronavirus test
XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) CEO Hugh Rogers tells Proactive the firm is pleased to be able to trade its shares on the OTCQB to gain access to a wider investor base.
Rogers says what's more, the development of its rapid saliva-based coronavirus (COVID-19) test is proceeding at an expedited basis at its diagnostic partner’s research lab in Germany.
Rogers says what's more, the development of its rapid saliva-based coronavirus (COVID-19) test is proceeding at an expedited basis at its diagnostic partner’s research lab in Germany.
People In This Video
No users are tagged in this video
